Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 mrt 2008 - 13:54
Statutaire naam
Crucell N.V.
Titel
Crucell Announces STAR® Research License Agreement with Medarex Inc
Bericht
Leiden, The Netherlands, 25 March, 2008 – Dutch biotechnology company Crucell N.V. today announced a non-exclusive STAR® research license agreement with biopharmaceutical company Medarex for the production of monoclonal antibodies. Financial details of the agreement were not disclosed.
About STAR® Technology
STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements, that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs.
Gerelateerde downloads
Datum laatste update: 05 februari 2025